Avila-Martin et al., 2015,2-OHOA and peripheral neuropathic pain.doi: 10.1002/ejp.528
Avila-Martin G et al., 2017., Treatment with albumin-hydroxyoleic acid complex restores sensorimotor function in rats with spinal cord injury: Efficacy and gene expression regulation.doi: 10.1371/journal.pone.0189151
Avila-Martin G et al., 2017., Efficacy and gene expression regulation doi: 10.1371/journal.pone.0189151
Chen L et al., 2015., J Clin Invest., doi: 10.1172/JCI80011.
David et al., 2021., Bioactive Lipid Mediators in the Initiation and Resolution of Inflammation after Spinal Cord Injury. doi: 10.1016/j.neuroscience.2021.04.026.
Hung et al., 2017., Targeting cytokines for treatment of neuropathic pain. doi: 10.1016/j.sjpain.2017.08.002
Jiang Fet al., 2017., Crosstalk between Notch and Sonic hedgehog signaling in a mouse model of amyotrophic lateral sclerosis. Neuroreport. doi: 10.1097/WNR.0000000000000725.
Kuffler et al., 2020., Mechanisms for Reducing Neuropathic Pain. doi: 10.1007/s12035-019-01757-9
Kuffler et al., 2020., Mechanisms for Reducing Neuropathic Pain. doi: 10.1007/s12035-019-01757-9
Liu et al., 2010., Phospholipase A2 and its Molecular Mechanism after Spinal Cord Injury. doi: 10.1007/s12035-010-8101-0.
Pablo V. Escribá., 2017., Membrane-lipid therapy: A historical perspective of membrane-targeted therapies — From lipid bilayer structure to the pathophysiological regulation of cells. doi: 10.1016/j.bbamem.2017.05.017.
Santos-Nogueira et al., 2015., Activation of Lysophosphatidic Acid Receptor Type 1 Contributes to Pathophysiology of Spinal Cord Injury. doi: 10.1523/JNEUROSCI.4703-14.201
Ueda., 2021., Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain. doi: 10.1016/j.plipres.2020.101079